Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Ford Robert B

Morrone Louis H.

Cushman Elizabeth C.

MCCOY JOHN A. JR.

Moreland Mary K

Salvadori Daniel Gesua Sive

Shroff Eric

STARKS DANIEL J

The National Advertising Division ruled on a challenge by Abbott Laboratories against Kendamil infant formula. While NAD supported claims about whole milk ingredients, it recommended Kendamil discontinue or modify claims regarding nutritional superiority over competitors, breast milk comparisons, HMO immune health benefits, and brand heritage dating to 1962. Kendamil stated it will comply with NAD's recommendations.

National Advertising Division Finds Certain Kendamil Infant Formula Claims Supported; Recommends Others Be Modified or Discontinued

The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.

Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

Abbott (ABT) declined 2.2% to $111.59 in the latest trading session, underperforming the S&P 500's 0.72% gain. Despite the daily decline, the company has appreciated 5.65% over the past month. Analysts project strong earnings growth with expected EPS of $1.43 (up 10% YoY) and quarterly revenue of $12.91 billion (up 13.52% YoY). Abbott holds a Zacks Rank of #3 (Hold) with a Forward P/E of 20.66, trading at a slight discount to its industry average.

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.

Global Blood-Based Biomarkers Market to Witness Upsurge in Growth at a CAGR of ~9% by 2034 | DelveInsight

The global laboratory informatics market is projected to grow at a CAGR of 5.06% from 2025 to 2035, driven by increased data processing demands, regulatory compliance requirements, and adoption of cloud-native solutions and AI-driven analytics. North America leads with 42.55% market share, while Asia-Pacific is the fastest-growing region. Services and LIMS products dominate, with cloud delivery and electronic lab notebooks showing the strongest growth rates.

Laboratory Informatics Market to Grow from USD 4.08 Billion in 2025 to USD 6.69 Billion by 2035, at a CAGR of 5.06% - SNS Insider

Teaching traders how to trade with conviction.

Flow Education @ BullFlow https://t.co/iWqwhYLiqb
Live Trading @ Stock Talk Insiders https://t.co/8mopfzD9l9

Danny Naz

Research-driven investor & position trader. Fundamental + Technical Analysis | Market Leaders
Not financial advice.

Abbott Laboratories (ABT) Stock Price, Analysis & Trade Signals